Navigation Links
PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
Date:4/30/2013

s, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses "including the recent acquisition of Liquent, Inc.", or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2012 as filed with the SEC on February 4, 2013, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

 PAREXEL International CorporationConsolidated Condensed Statement of Operations(Unaudited)Three Months EndedNine Months Ended(in thousands, except per share data)March 31, 2013March 31, 2012March 31, 2013March 31, 2012Service revenue$ 454,493$ 355,992$ 1,271,314$ 1,003,897Reimbursement revenue68,95856,037197,794156,592Total revenue523,451412,0291,469,1081,160,489Costs and expenses:Direct costs311,917241,445892,646691,718Reimbursable out-of-pocket expenses68,95856,037197,794156,592Selling, general and administrative 88,03867,159229,975192,506Depreciation15,77315,16646,03044,199Amortization2,8912,1986,0186,542Restructuring (benefit) charge(732)1,807(1,150)5,669Total costs and expense
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. UV Flu Technologies Expands Its International Footprint
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Md., Dec. 4 MedImmune today announced that,it has ... chronic asthma to,determine the safety of subcutaneous dosing of ... (IL-5R). Preclinical data,suggest that inhibiting the IL-5R pathway may ... supporting continued study of this antibody. , ...
... Azur Pharma Limited ("Azur") today,announced that it has ... ("BioSante")(Nasdaq: BPAX ) to acquire U.S. ... formulation of estradiol which is,indicated for the treatment ... Elestrin was approved by the U.S. Food and ...
... Introduces New Trade Name Onrigin(TM) for Laromustine , , ... (OTC Bulletin Board: VION) today made several announcements related to events ... the Moscone Center in San Francisco from December 6-9, 2008. ... , , The Company announced ...
Cached Biology Technology:MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 2Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 3Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting 4
(Date:4/23/2014)... study by a University of Exeter researcher has shed ... wild camels thriving in Australia,s remote outback have become ... , Sarah Crowley, of the Environment and Sustainability Institute ... history of the camel in Australia, from their historic ... their current status as unwelcome "invader." , The deserts ...
(Date:4/23/2014)... (April 23, 2014). "I think one can argue that if ... as doing everything else that we canthen we can solve ... one of the world,s foremost climate researchers, in the current ... by SAGE. Refusing to take significant action on climate change ... needed to address the problem, Wigley explains in an exclusive ...
(Date:4/22/2014)... April 22, 2014 Scientists from the Florida campus ... protein complex that plays a critical but previously unknown ... study, which showed a novel role for a protein ... the journal eLife , a publisher supported by ... and the Wellcome Trust. , "This is a critical ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... months of the First World War, a lethal virus ... swept the United States, Europe and Asia in three ... claimed up to 100 million victims, most of whom ... pneumonia. Many died within days of the first symptoms. ...
... by too many people, according to a new report published ... a Cell Press publication. Rather, the researchers found that the ... Indian Ocean depended mostly on the complexity of the reefs ... the shores., Specifically, they found, overfishing is at its worst ...
... to direct chemical modifications to specific sites on recombinant ... the pharmaceutical industry has been developed by Carolyn ... Energy,s Lawrence Berkeley National Laboratory and the University of ... for diabetes, can be made in bacterial systems like ...
Cached Biology News:Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5Rise or fall of reef fish driven by both economy and ecology 2Tailor-made recombinant proteins in mammals 2Tailor-made recombinant proteins in mammals 3Tailor-made recombinant proteins in mammals 4
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
Biology Products: